Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register. Issue 7 (14th July 2022)

• Record Type: Journal Article
• Authors: Thunberg, Joel; Björkqvist, Olle; Hedin, Charlotte R. H.; Forss, Anders; Söderman, Charlotte; Bergemalm, Daniel; Olén, Ola; Hjortswang, Henrik; Strid, Hans; Ludvigsson, Jonas F.; Eriksson, Carl; Halfvarson, Jonas
• Is Part Of: United European Gastroenterology journal. Volume 10:Issue 7(2022)
• Page Start: 631
• Page End: 639
• Publication Date: 2022-07-14
• Subjects: anti‐tnf‐antibodies -- inflammatory bowel disease -- ulcerative colitis -- ustekinumab; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1002/ueg2.12275
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract: Background: Real‐world data on clinical outcomes of ustekinumab in ulcerative colitis are lacking. Objective: To assess short‐ and long‐term clinical outcomes of ustekinumab in ulcerative colitis. Methods: Adult ulcerative colitis patients without previous colectomy starting ustekinumab treatment up until 11 December 2020 were identified through the Swedish Inflammatory Bowel Disease Register (SWIBREG). Prospectively recorded data were extracted from the SWIBREG. The primary outcome was persistence to ustekinumab 16 weeks after treatment initiation. Secondary outcomes included drug persistence beyond week 16, clinical remission (defined as a patient‐reported Mayo rectal bleeding subscore = 0 and stool frequency subscore ≤1), biochemical remission (defined as faecal‐calprotectin <250 μg/g) and changes in health‐related quality of life (HRQoL), as measured by the Short Health Scale (SHS). Logistic regression was used to identify potential predictors of ustekinumab persistence at 16 weeks. Results: Of the 133 patients with ulcerative colitis, only three were naïve to biologics and tofacitinib. The persistence rates of ustekinumab were 115/133 (86%) at 16 weeks and 89/133 (67%) at last follow‐up, that is, after a median follow‐up of 32 (interquartile range 19–56) weeks. The clinical remission rates were 17% at 16 weeks and 32% at the last follow‐up. The corresponding rates for biochemical remission were 14% and 23%. The median faecal‐calprotectin concentration decreased from 740 μg/g at baseline to 98 μg/g at the last follow‐up ( p < 0.01, n = 37). Improvement was seen in each dimension of the SHS between baseline and last follow‐up ( p < 0.01 for each dimension, n = 46). Male sex was associated with ustekinumab persistence at 16 weeks (adjusted odds ratio = 4.00, 95% confidence interval: 1.35–11.83). Conclusion: In this nationwide real‐world cohort of ulcerative colitis patients with prior drug failures, including other biologics and tofacitinib, ustekinumab was associated with high drug persistence rates and improvements in clinical, biochemical and HRQoL measures.